CareDx (CDNA) Stock Price, News & Analysis

Company Overview

CareDx, Inc. (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring. CareDx also offers a range of clinical laboratory services and companion diagnostic solutions that support patient management in lung and liver transplantation.

Headquartered in Brisbane, California, CareDx serves transplant centers across the United States, Europe and select international markets. The company operates a network of CLIA‐certified laboratories and collaborates with academic institutions and transplant centers to advance research in immunological monitoring and personalized patient care.

CareDx was established through the integration of Viracor-IBT and Transplant Genomics in 2018, building on more than a decade of molecular diagnostic expertise. The company’s leadership team comprises seasoned professionals with backgrounds in biotechnology, laboratory operations and clinical research, all dedicated to improving outcomes for transplant recipients worldwide.

Key Stats

• Today's Range: $46.05 to $48.72
• 50-Day Range: $23.25 to $48.61
• 52-Week Range: $12.28 to $49.76
• Volume: 1.16 million shs
• Average Volume: 1.17 million shs
• Market Capitalization: $2.51 billion
• P/E Ratio: 23.48
• Dividend Yield: N/A
• Price Target: $47.75
• Consensus Rating: Moderate Buy

CareDx Stock Analysis - MarketRank™

CareDx scored higher than 60% of companies evaluated by MarketBeat, and ranked 358th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 2 buy ratings, 4 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for CareDx is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

CareDx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 34.04%

Earnings Growth

Earnings for CareDx are expected to grow by 34.04% in the coming year, from $0.47 to $0.63 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CareDx is 23.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.45.

Price to Earnings Ratio vs. Sector

The P/E ratio of CareDx is 23.48, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.60.

Price to Book Value per Share Ratio

CareDx has a P/B Ratio of 5.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.15% of the float of CareDx has been sold short.

Short Interest Ratio / Days to Cover

CareDx has a short interest ratio ("days to cover") of 4.25.

Change versus previous month

Short interest in CareDx has recently decreased by 0.84%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CareDx does not currently pay a dividend.

Dividend Growth

CareDx does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.45

News Sentiment

CareDx has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for CareDx this week, compared to 4 articles on an average week.

Search Interest

Only 8 people have searched for CDNA on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

4 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,770,348.00 in company stock.

Percentage Held by Insiders

2.40% of the stock of CareDx is held by insiders.

Percentage Held by Institutions

CareDx has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 8/23/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CDNA
• CIK: 1217234
• Web: www.caredxinc.com
• Phone: (415) 287-2300
• Fax: 415-287-2450
• Employees: 740
• Year Founded: 2000

Price Target and Rating

• Average Price Target for CareDx: $47.75
• High Price Target: $64.00
• Low Price Target: $21.00
• Potential Upside/Downside: -1.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.07
• Trailing P/E Ratio: 23.48
• Forward P/E Ratio: 103.43
• P/E Growth: N/A
• Net Income: -$21.35 million
• Net Margins: 24.23%
• Pretax Margin: 25.15%
• Return on Equity: 2.87%
• Return on Assets: 2.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.58
• Quick Ratio: 4.51

Sales & Book Value

• Annual Sales: $379.80 million
• Price / Sales: 6.62
• Cash Flow: $0.01 per share
• Price / Cash Flow: 7,463.08
• Book Value: $8.23 per share
• Price / Book: 5.91

Miscellaneous

• Outstanding Shares: 51,730,000
• Free Float: 50,492,000
• Market Cap: $2.51 billion
• Optionable: Optionable
• Beta: 2.39